Loading...
•
Sep 30, 2020
Integra LifeSciences Q3 2020 Earnings Report
Integra LifeSciences' third quarter performance exceeded expectations due to recovery trends and solid execution.
Key Takeaways
Integra LifeSciences reported Q3 2020 revenues of $370.2 million, a decrease of 2.3% on a reported basis and 1.5% organically. GAAP EPS was $0.38, compared to a loss of ($0.32) in Q3 2019, while adjusted EPS was $0.80, up from $0.68. The company's full-year 2020 guidance remains withdrawn.
Reported revenues were $370.2 million, a decrease of 2.3% on a reported basis and a decrease of 1.5% on an organic basis compared to the prior year.
GAAP earnings per diluted share were $0.38, compared to a GAAP loss of ($0.32) in the third quarter of 2019.
Adjusted earnings per diluted share were $0.80, compared to $0.68 in the prior year.
The Company's full-year 2020 guidance remains withdrawn due to the uncertainty related to COVID-19 and ongoing variability in the recovery in surgical procedure volumes.
Revenue by Segment
Forward Guidance
Due to the ongoing uncertainty around the scope and duration of the pandemic and the timing of recovery across the globe, the Company’s guidance for the full-year 2020 remains withdrawn. Barring significant worsening of the pandemic, the Company expects further sequential revenue improvement in the fourth quarter.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...